The molecular biology of lung cancer brain metastasis: an overview of current comprehensions and future perspectives

Masaki Hanibuchi¹, Sun-Jin Kim², Isaiah J. Fidler², and Yasuhiko Nishioka¹

¹Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan, ²Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, USA

Abstract: Brain metastases occur in 20-40% of patients with advanced malignancies and lung cancer is one of the most common causes of brain metastases. The occurrence of brain metastases is associated with poor prognosis and high morbidity in patients with advanced lung cancer, even after intensive multimodal therapy. Progress in treating brain metastases has been hampered by a lack of model systems, a lack of human tissue samples, and the exclusion of brain metastatic patients from many clinical trials. While the biology of brain metastasis is still poorly understood, it is encouraging to see more efforts are beginning to be directed toward the study of brain metastasis. During the multi-step process of metastasis, functional significance of gene expressions, changes in brain vasculature, abnormal secretion of soluble factors and activation of autocrine/paracrine signaling are considered to contribute to the brain metastasis development. A better understanding of the mechanism of this disease will help us to identify the appropriate therapeutic strategies, which leads to circumvent brain metastases. Recent findings on the biology of lung cancer brain metastases and translational leads identified by molecular studies are discussed in this review. J. Med. Invest. 61 : 241-253, August, 2014

Keywords: brain metastasis, lung cancer, molecular biology

I. INTRODUCTION

Brain metastases constitute the most frequent malignant disease in the central nervous system (CNS), outnumbering primary brain tumor cases 10-fold. (1) Up to 20-40% of patients with adult systemic malignancies will develop brain metastases in the course of their disease (2). A variety of systemic malignancies can metastasize to the CNS, although the majority of the lesions come from lung cancer.
Followed by breast cancer (20-30%), melanoma (5-10%), lymphoma, and various other primary sites like the gastrointestinal tract (4-6%) and prostate (3, 4). Brain metastasis represents a significant healthcare problem and has an adverse impact on patient morbidity and outcome (5). In addition, tumors in the CNS strongly affect patients’ quality of life (QOL), impairing sensory and motor neural functions and inducing headache, nausea, vomiting, and seizures (6). While conventional treatment regimens provide marginal survival benefits (7), the prognosis for patients with brain metastases is dismal. With an increasing incidence (8), and a frequent occurrence in patients whose extracranial cancer has been controlled, brain metastasis is becoming a major limiting factor for cancer patients’ QOL and survival.

Lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is the leading cause of malignancy-related death worldwide. Lung cancer is the malignancy that most commonly gives rise to brain metastases. Approximately 10-25% of lung cancer patients have brain metastases at initial diagnosis and about 40-50% of them develop brain metastases during the course of disease (9). Treatment options are limited and standard of care is generally whole brain radiation therapy (WBRT) with corticosteroids to alleviate edema and overall survival is 3-6 months after diagnosis of CNS disease. Favorable prognostic factors that affect survival include Karnofsky’s performance status, patient age (< 65 years), control of primary tumor, and absence of extracranial metastatic disease (10).

To overcome lung cancer brain metastases, an understanding of the molecular biology of brain metastasis is crucial. The current review gives a broad overview about the accumulating recent knowledge of lung cancer brain metastasis and the latest developments in the field.

II. BIOLOGY OF BRAIN METASTASIS

Similar to the metastatic process in other organs, brain metastasis formation is a highly selective, multi-step process, involving complex interactions between tumor and host cells, which is clearly explained by the “seed-and-soil” hypothesis (11, 12).

The brain is considered as a “sanctuary” site for metastatic cancer cells because many of the therapeutic agents can not cross the blood-brain barrier (BBB) (13). The BBB is a network composed of both endothelial cells and supporting components that protects the CNS microenvironment. In contrast to the periphery, the endothelium of brain micro-vessels is characterized by continuous tight junctions (TJs), decreased pinocytosis activity, very low pinocytic activity, and overexpressed efflux pumps (14) (Figure 1). With the reinforcement of the surrounding extracellular matrix (ECM), basal membrane, pericytes, and the end-feet of astrocytes, the BBB effectively prevents the free exchange of substances between the blood and the interstitial fluid of the brain (15). Therefore, the brain forms a special challenge for tumor cells because of BBB and all other steps have to be successfully completed.

![Figure 1](image_url)
for tumor cells to invade through BBB and survive.

When metastatic cancer cells enter the brain circulation, they might arrest in sites of slow flow within the capillary bed at vascular branch points. Then, interactions between cancer cells and brain endothelial cells or transendothelial migration are mediated by interaction of tumor cell-surface receptors and endothelial cell adhesion molecules (16). After overcoming the BBB, tumor cells are confronted with components of the local microenvironment including the extracellular matrix (ECM), resident brain parenchymal cells (astrocytes, microglia), and paracrine signaling molecules including cytokines and growth factors (16). Survival and successful tumor growth require adaption to and interaction with these factors. The brain also establishes an adequate blood supply via angiogenesis, angioectasia, vasculogenesis, vasculogenic mimicry, making brain metastases grow and proliferate better (17). During the above process, functional significance of gene expressions, changes in brain vasculature, abnormal secretion of soluble factors and activation of autocrine/paracrine signaling contribute to the brain metastasis development.

III. MOLECULAR PATHWAYS MEDIATING LUNG CANCER BRAIN METASTASIS

1. Gene expression analyses

In order to identify pathways specific to the development of brain metastasis and novel molecular targets/translational leads, several groups have undertaken gene expression studies in animal models and human tissue cohorts.

Kikuchi et al. compared gene expression of primary lung adenocarcinoma with brain metastases originating from these tumors. Of 23,040 genes tested, 244 showed a different expression level, including genes coding for plasma membrane proteins, cellular antigens and cytoskeletal proteins, which may modulate cell-cell interactions (18). Brain metastases of lung adenocarcinoma were evaluated in another study as well, by comparing the gene expression profile of metastatic brain tumors originating from lung adenocarcinoma with that of healthy lung. Zohrabian et al. have found 1,561 differentially expressed genes by using cDNA microarray. The overexpression of genes associated with invasion and metastasis, adhesion, angiogenesis and cell migration was validated by real-time PCR (19).

In a cohort of primary tumors from lung cancer patients who developed brain metastases, Grinberg-Rashi et al. found the expression levels of three genes, CDH2, KIFC1, and FALZ, was highly predictive of brain metastases (20). N-cadherin, which is coded by CDH2 gene, is involved in multiple processes including inducing invasion, migration, promoting survival of cancer cells, regulating adhesion and neurite outgrowth (21). Clinically, N-cadherin overexpression has been shown to be associated with decreased survival in poorly differentiated SCLCs (22).

DCUN1D1, a squamous cell carcinoma-related oncogene, is associated with tumor progression and poor outcomes in NSCLC. Recently, the overexpression of DCUN1D1 has been found to be useful in identifying patients who are at higher risk for brain metastases. Yoo et al. showed that 14 of 16 DCUN1D1-positive NSCLC patients (87.5%) resulted in brain metastases (23).

However, as previously reported in other primary and metastatic clinical or experimental tumors (24-26), the genetic heterogeneity would limit the translation of the gene profiles into the clinical trials.

2. Cell surface molecules

1) Integrins

Integrins are a family of cell surface receptors that mediate cell adhesion and signal transduction. Integrins interact with ECM components such as collagen, laminin, and fibronectin and play crucial roles in cell migration. Integrins can also activate signaling cascades to mediate cell survival (27). The expression of integrin α3β1 has been associated with lung cancer brain metastasis. Compared with their parental cell line and bone-metastasizing counterparts, tumor cells that preferably metastasize to the brain highly expressed α3β1 integrin (28). Moreover, inhibiting α3β1 integrin function decreased brain metastases formation in nude mice (28). It has been posited that the interaction of the α3β1 integrin with laminin, which promotes tumor cell migration and invasion, may be critical to this effect (28).

2) Immunoglobulin superfamily of cell adhesion molecules

Endothelial cells express several adhesion molecules belonging to the immunoglobulin superfamily, including members of the intercellular adhesion molecules (ICAMs), vascular-cell adhesion molecule (VCAM) and platelet-endothelial-cell adhesion molecule (PECAM) (29). These are essential in immune
response and inflammation, but some of them were also shown to be involved in the interaction of vascular endothelial and tumor cells and formation of metastases. Recently, ICAM-1 and VCAM-1 were shown to play a crucial role in polychlorinated biphenyl-mediated enhancement of brain metastasis formation of lung carcinoma cells (30).

3) Cadherins

Cadherin dysfunction is involved in tumor progression and metastasis formation. Loss of expression of E-cadherin induces epithelial-mesenchymal transition (EMT) in carcinoma cells, which initiates an increase in cell motility and metastasis formation. In metastatic lesions, a re-expression of E-cadherin has been observed, which plays an important role in the proliferation of tumor cells at the metastatic site. Correspondingly, metastatic brain tumors were shown to express high levels of E-cadherin (31), while low expression of E-cadherin in primary NSCLC was shown to correlate with increased risk for the development of brain metastasis (32). In addition, the expression level of N-cadherin was observed to be highly predictive of brain metastasis formation in NSCLC (20).

3. Soluble factors

1) Vascular endothelial growth factor (VEGF)

Angiogenesis is an important aspect of tumor metastasis. Recent studies have examined the roles of VEGF, which influences both angiogenesis and blood vessel permeability. VEGF signaling and function in brain metastasis has also been extensively characterized in preclinical models. Measurement of VEGF levels in the culturing media of cells growing in vitro has shown that VEGF is secreted by tumor cells with high brain metastatic activity (33). Increased VEGF secretion has also been detected in brain metastasis xenografts in nude mouse models (33). Antisense VEGF transfectants of PC14-PE6 lung adenocarcinoma cells exhibited a decreased incidence of experimental brain metastases, suggesting that VEGF is necessary for brain tumor initiation and growth (33). Jubb et al. compared VEGF expression, proliferation, microvessel density, vascular pattern and vascular maturity in matched primary NSCLC and brain metastases (34). They found that brain metastases are characterized by a significantly higher proliferation rate and vascular maturity than their matched primaries. These findings are important because if the vasculature of brain metastasis is mature, then patients with cerebral secondaries may be less likely to respond to anti-VEGF treatment, even though patients with primary NSCLC might benefit from such therapy (34).

2) Placental growth factor (PIGF)

Li et al. (35) recently found PIGF, a member of VEGF subfamily, may be associated with SCLC brain metastasis. PIGF in the serum of SCLC patients with brain metastases was significantly higher than that without brain metastases and normal specimens. In addition, SCLC cell-derived PIGF activates the VEGFR1/Rho/ERK signaling pathway in cerebral endothelial cells, resulting in the disassembly of TJs and promoting transendothelial migration (35). Moreover, the down-regulation of PIGF suppressed SCLC cell metastasis to the brain in an experimental brain metastasis model.

3) Chemokines

Chemokines play an important role in cell migration, invasion and tumor angiogenesis (36). Emerging data support the putative involvement of the CXCR4/CXCL12 signaling axis in NSCLC brain metastasis (37). High CXCL12 expression within sites of lung cancer metastasis has been demonstrated in mouse xenograft studies (38). Hartmann et al. showed that the CXCR4 chemokine receptor closely co-operates with integrins to promote adhesion and chemoresistance of SCLC cells (39). Overexpression of CXCR4 and CXCL12 has been described in histopathological specimens of brain metastases and correlated with brain-specific metastasis in a cohort of NSCLC patients (40). In a recent study, Paratore et al. (41) have investigated the expression of CXCR4/CXCL12 in primary NSCLC specimens of patients with and without brain metastases. CXCL12 and CXCR4 immunoreactivities in metastatic NSCLC samples were significantly higher than that in paired non-metastatic NSCLC.

4. Proteases

1) Matrix metalloproteinases (MMPs)

Different proteolytic enzymes have been implicated in brain metastasis formation and migration of tumor cells through BBB endothelial cells. MMPs might have special importance in the process of transendothelial migration of tumor cells through the BBB, because TJ proteins can be targets of MMP degradation. MMP-induced disruption of TJs was shown to promote invasion of tumor cells into the CNS (42). MMP-9 was reported to be overexpressed by brain metastatic lung adenocarcinoma cells (43).

2) A disintegrin and metalloprotease 9 (ADAM9)

ADAM-9 is a membrane-tethered protease and
belongs to a member of the “a disintegrin and metalloprotease” family. ADAM9 is overexpressed in brain metastatic lung cancer cells. Shintani et al. found that the expression of ADAM9 up-regulated integrin α3β1 and facilitated brain metastasis formation (44).

5. Driver mutations

1) Epidermal growth factor receptor (EGFR) mutations

It is found that driver mutations in NSCLC, at least in part, would be associated with brain metastases. In East Asian patients, Matsumoto et al. (45) and Gow et al. (46) have found EGFR mutations in 63 and 44% of brain metastases, respectively. This prevalence is similar to that reported in primary tumors of the same population, varying from 30 to 50% (47, 48). Among the 110 patients enrolled, Li et al. found the frequencies of EGFR mutations were 64% and 31% in the patients with and without brain metastases, respectively (49). Eichler et al. showed that the numbers of brain metastases were significantly higher in patients with EGFR-mutated NSCLC compared to those with wild-type (50). Sekine et al. demonstrated that NSCLC patients with the exon 19 deletions had more multiple and smaller brain metastases with smaller peritumoral brain edema than those without any mutations (51). Moreover, Heron et al. (52) reported that tumors with exon 19 deletions showed a higher incidence of CNS involvement as compared with tumors bearing a L858R mutation (21% vs. 3%). While little is known about the behavior of tumor cells during transmigration through the BBB, it has been shown that inhibition of ROCK decreases the migration of SCLC cells through the brain endothelium (61).

2) Anaplastic lymphoma kinase (ALK) translocations

More recently, ALK translocations have been found to be another “druggable” alteration besides activating EGFR mutations in NSCLC (53). ALK translocations appear to be constant between primary tumors and brain metastases (54), and ALK-positive tumors may predispose to brain metastasis formation (55). In contrast, Doebele et al. found patients with ALK translocations were predisposed to liver, but not adrenal, bone, or brain metastases, compared to ALK-negative cohort (56). Further studies should be required to clarify the significance of ALK translocations in NSCLC patients with brain metastases.

6. Growth factors and signaling pathways

1) Wnt signaling

The activation of canonical Wnt/TCF pathway has also been identified as playing a role in lung cancer spread to the brain. Treatment of a brain-seeking lung cancer cell line H2030-BrM3 with Wnt3a significantly increased the expressions of the WNT/TCF target genes, LEF1 and HOX89. Confirming that LEF1 and HOX89 are involved in metastasis, overexpression of the two genes led to an increase in brain metastases whereas knockdown of each gene decreased metastatic incidence (57). Supporting the hypothesis that TCF4 may play an important role in lung cancer development, Xu et al. found increased TCF4 overexpression in lung cancer patients with advanced stages (stage III-IV) compared with early stages (stage I-II) (58). Furthermore, expression of Wnt3a in a four-gene signature predicted increased mortality rates in lung cancer patients (59).

2) Rho/Rho kinase (ROCK) signaling

During invasion of tissues and migration through vessel walls and ECM components, metastasizing tumor cells require increased motility, which is dependent on the remodeling of the cytoskeleton. Rho/ROCK pathways had been proposed to be involved in the regulation of paracellular permeability and junctional dynamics in endothelial cells (60). While little is known about the behavior of tumor cells during transmigration through the BBB, it has been shown that inhibition of ROCK decreases the migration of SCLC cells through the brain endothelium (61).

3) Hepatocyte growth factor (HGF)/Met signaling

The receptor tyrosine kinase Met and its ligand HGF promoted metastatic spread to the lung, liver and brain in an experimental model using the NCI-H460 lung cancer cell line (62). A study of matched lung cancer brain metastases and primary tumors from the same patients identified increased expression of total and phosphorylated c-Met in the brain metastases. The expression and activation of c-Met in the primary lung tumors also correlated with the development of brain metastases (63).

4) Phosphoinositide 3-kinase (PI3K)-Akt signaling

The PI3K-Akt pathway is a crucial regulator of cell survival and proliferation, and increased PI3K activity has been reported in several cancer types. Recently, a PI3K inhibitor was found to effectively control metastatic growth of HER2-positive breast cancer cells in multiple organs, including brain metastases (64). However, inhibition of PI3K had no effect on the transmigration of SCLC cells through brain endothelial cells (61).
5) Endothelin (ET)/ET receptor signaling
The binding of ET to the ET receptors exerts pleiotropic biological effects that influence cell survival, proliferation, invasion, metastasis, as well as angiogenesis (65). In a preclinical model of spontaneous melanoma brain metastasis, Cruz-Muñoz et al. have identified the alterations in the expression of ET receptor as a potential factor that influences brain metastatic potential. Induced overexpression of this gene mediated enhanced overall metastatic disease, and resulted in an increased incidence of spontaneous brain metastases (66). We recently demonstrated that the blockade of ET receptor significantly inhibited experimental brain metastases of human NSCLC cells (67).

7. MicroRNA (miRNA)
Mounting evidence indicates that miRNA may be key players in the regulation of tumor cell invasion and metastasis. Chen et al. (68) found miR-378 was significantly differentially expressed in the matched NSCLC surgical specimens from 8 patients with brain metastases and 21 without brain metastases. Arora et al. (69) reported that miR-328 had a role in conferring migratory potential to NSCLC cells, which might be incorporated into clinical treatment decision making to stratify NSCLC patients at higher risk for brain metastases.

8. Single nucleotide polymorphisms (SNPs)
Studying multiple SNPs in signaling pathways may be useful for pinpointing the genes and polymorphisms involved in conferring risk of brain metastases (70). Multivariate analyses of 33 SNPs from 13 genes in the transforming growth factor-β (TGF-β) signaling pathway have revealed that the GG genotype of SMAD6 : rs12913975 and TT genotype of INHBC : rs4760259 were associated with a significantly higher incidence of brain metastasis in patients with NSCLC at 24 months follow-up, compared with the GA or CT/CC genotypes, respectively (71). In melanoma, TGF-β2 was reported to be crucial, since its expression is indispensable for the metastasis formation in the brain parenchyma (72).

9. Circulating markers
1) Tumor markers
Tumor markers may be helpful in the prediction of brain metastases. Among them, carcinoembryonic antigen (CEA) is the most widely studied. Lee et al. found that the pretreatment serum CEA level was significantly correlated with brain metastases in 227 advanced NSCLC patients (73). Arrieta et al. also reported that high serum CEA level at diagnosis is an independent prognostic factor of CNS metastasis development and survival in patients with advanced NSCLC (74). They considered that surface expression of CEA in tumor cells could be a mechanism of invasion to CNS through immunoglobulin-related transport in BBB.

Pro-gastrin-releasing peptide (ProGRP) is a widely used tumor marker for the screening of SCLC. Yonemori et al. retrospectively analyzed the characteristics of the first failure event due to brain metastasis in SCLC patients treated with prophylactic cranial irradiation (PCI). Elevation of ProGRP level before PCI was found to be a significant predictive factor for brain metastasis on multivariate analysis (75).

2) Indicators of CNS injury in the blood
Elevated levels of certain proteins or neurotransmitters in the blood may be indicators of CNS damage caused by invasion of brain metastases (70). S100β is a nervous system specific cytoplasmic protein found in astrocytes and is released into serum when the BBB is breached (76). However, a confounding factor was the presence of BBB changes due to cerebrovascular disease. Therefore, patients who are found to have evidence of chronic cerebrovascular disease will likely receive no further benefit from routine screening of their serum S100β level. More recently, proapolipoprotein A1, the precursor of the cholesterol-binding protein apolipoprotein A1, was reported to be significantly increased in patients with CNS disease compared with those affected only by vascular diseases (77).

10. Role of astrocytes in brain metastasis formation
Astrocytes have an indispensable role in the maintenance of BBB properties of cerebral endothelial cells. Therefore, they support endothelial cells in impeding tumor cells from penetrating into the brain. On the other hand, astrocytes have a protective role for brain metastases. Reactive astrocytes induce the protection of tumor cells from chemotherapy through sequestration of calcium from the cytoplasm of tumor cells and by up-regulating survival genes in tumor cells (78, 79). Moreover, astrocytes secrete soluble factors that stimulate the proliferation of tumor cells in the brain microenvironment. In addition, astrocytes were shown to induce proliferation of lung and breast cancer cells by producing interleukin (IL) -1β, tumor necrosis factor-α
IV. TARGETED THERAPIES FOR LUNG CANCER BRAIN METASTASIS

In the study by Kienast et al., the VEGF-A inhibitor bevacizumab blocked angiogenesis and resulted in dormancy of brain metastasis derived from lung cancer cells (82), indicating that anti-angiogenic agents might be promising to inhibit brain metastasis. In early clinical studies, hemorrhagic episodes were reported after treatment with bevacizumab in patients with metastatic spread, including brain metastasis (83). In consequence, guidelines prohibited the use of bevacizumab in this cohort and patients with brain metastasis have been excluded from participating in clinical trials that investigated anti-angiogenic drugs (84, 85). However, recent large meta-analyses performed in over 10,000 patients that received anti-angiogenic agents revealed that these drugs do not increase the risk of intracranial bleeding compared to the untreated population with brain metastasis (0.8-3.3% bleeding risk) (85). These reports have prompted to change the guidelines and allow administration of bevacizumab in patients with brain metastasis from non-squamous NSCLC (84). Based on the new guidelines, the decision to use anti-angiogenics in this patient cohort should be made upon careful assessment of the potential benefits and risks for individual patients (85).

The EGFR tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, have been tested in patients with NSCLC and brain metastasis (50, 86, 87). Similar to primary tumors, the response of brain metastasis to EGFR inhibitors is better in patients with activating EGFR mutations while the activity of these drugs in individuals with wild-type EGFR metastatic disease is very modest (50, 86, 87). Interestingly, the response of chemotherapy-naïve, never-smoker patients with brain metastases after treatment with erlotinib and gefitinib was 74%, and maybe inhibition of EGFR in this patient subgroup is more effective compared to other cohorts (88). The BBB penetrability of erlotinib might be better than gefitinib as small but measurable penetration of erlotinib into cerebrospinal fluid (CSF) has been documented (89). Notably, the incidence of CNS progression after treatment with gefitinib or erlotinib was lower in NSCLC patients with EGFR mutations compared to patients with wild-type EGFR and therefore these targeted agents might also have a value as prophylactic agents (52). Furthermore, the resistance EGFR mutation T790M occurs also in CNS metastasis. Whether afatinib, a second generation EGFR inhibitor that inhibits T790M also has activity in CNS metastasis with this mutation remains to be determined. In one report, encouragingly, dose escalation of afatinib resulted in remission of a brain metastasis (90). The question whether erlotinib or gefitinib should be combined with other WBRT or stereotactic radiosurgery is subject of current studies.

Activation of ALK oncogene leads to fusion of ALK and the echinoderm microtubule-associated protein-like 4 (EML4) that is encountered in approximately 4% of patients with NSCLC. The targeted agent crizotinib inhibits this oncogenic fusion and can lead to effective local tumor control (91). In a recent case report of a patient with EML4-ALK fusion, though, brain metastasis developed despite control of extracerebral metastases (92). Very low levels of crizotinib were detected in plasma and CSF of the patient, suggesting insufficient BBB penetrability for this agent (92). However, another recent case report demonstrated a twelve-month progression-free survival after treatment with crizotinib in a patient with lung adenocarcinoma with EML4-ALK fusion that developed metachronous miliary lung metastases and brain metastasis (93).

V. CONCLUSION

Brain metastasis has become an increasingly challenging clinical problem, largely due to the recently improved clinical control of systemic metastatic diseases. While the biology of brain metastasis is still poorly understood, it is encouraging to see more efforts are beginning to be directed toward the study of brain metastasis.

The biomarkers mentioned in this review would be promising tools for the prediction of brain metastases. However, currently none of them can predict occurrence of brain metastases alone and much challenge remain for their translation into practice. In this article, the mechanistic basis of lung cancer metastasis to the brain is described (Table 1). The better understanding of molecular biology of lung cancer brain metastasis, including heterogeneous...
It is indisputable that the microenvironment cells genetic profiles, is essential to find appropriate targets of prevention of brain metastasis formation. In addition, prospective randomized clinical studies are needed to further assess the utility of these biological markers.

### Table 1. Risk factors for the development of lung cancer brain metastasis.

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>Authors</th>
<th>Reference No.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>high CDH2 expression</td>
<td>Grinberg-Rashi H et al.</td>
<td>20</td>
</tr>
<tr>
<td>high KIFC1 expression</td>
<td>Grinberg-Rashi H et al.</td>
<td>20</td>
</tr>
<tr>
<td>low FALZ gene expression</td>
<td>Grinberg-Rashi H et al.</td>
<td>20</td>
</tr>
<tr>
<td>high DCUN1D1 expression</td>
<td>Yoo et al.</td>
<td>23</td>
</tr>
<tr>
<td><strong>Cell surface molecules</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>high α3β1 integrin expression</td>
<td>Yoshimasa T et al.</td>
<td>28</td>
</tr>
<tr>
<td>high ICAM-1 expression</td>
<td>Sipos E et al.</td>
<td>30</td>
</tr>
<tr>
<td>high VCAM-1 expression</td>
<td>Sipos E et al.</td>
<td>30</td>
</tr>
<tr>
<td>low E-cadherin expression</td>
<td>Yoo JY et al.</td>
<td>32</td>
</tr>
<tr>
<td>high N-cadherin expression</td>
<td>Saad AG et al.</td>
<td>9</td>
</tr>
<tr>
<td><strong>Soluble factors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>high VEGF expression</td>
<td>Saad AG et al.</td>
<td>9</td>
</tr>
<tr>
<td>high α3β1 integrin expression</td>
<td>Yoshimasa T et al.</td>
<td>28</td>
</tr>
<tr>
<td>high ICAM-1 expression</td>
<td>Sipos E et al.</td>
<td>30</td>
</tr>
<tr>
<td>high VCAM-1 expression</td>
<td>Sipos E et al.</td>
<td>30</td>
</tr>
<tr>
<td>low E-cadherin expression</td>
<td>Yoo JY et al.</td>
<td>32</td>
</tr>
<tr>
<td>high N-cadherin expression</td>
<td>Saad AG et al.</td>
<td>9</td>
</tr>
<tr>
<td><strong>Proteases</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>high MMP-9 expression</td>
<td>Hu L et al.</td>
<td>43</td>
</tr>
<tr>
<td>high ADAM9 expression</td>
<td>Shintani Y et al.</td>
<td>44</td>
</tr>
<tr>
<td><strong>Driver mutations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EGFR mutation</td>
<td>Li Z et al.</td>
<td>49</td>
</tr>
<tr>
<td>ALK translocation</td>
<td>Eichler AF et al.</td>
<td>50</td>
</tr>
<tr>
<td><strong>Signaling pathways</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>activation of WNT/TCF signaling</td>
<td>Nguyen DX et al.</td>
<td>57</td>
</tr>
<tr>
<td>activation of Rho/ROCK signaling</td>
<td>Li B et al.</td>
<td>61</td>
</tr>
<tr>
<td>activation of HGF/Met signaling</td>
<td>Navab R et al.</td>
<td>62</td>
</tr>
<tr>
<td><strong>Circulating markers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CEA elavation</td>
<td>Lee DS et al.</td>
<td>73</td>
</tr>
<tr>
<td>ProGRP elavation</td>
<td>Arrieta O et al.</td>
<td>74</td>
</tr>
<tr>
<td>Others</td>
<td></td>
<td></td>
</tr>
<tr>
<td>high Amphiregulin expression</td>
<td>Sun M et al.</td>
<td>75</td>
</tr>
<tr>
<td>low Caspase-3 expression</td>
<td>Saad AG et al.</td>
<td></td>
</tr>
<tr>
<td>high Caveolin-1 expression</td>
<td>Cassoni P et al.</td>
<td></td>
</tr>
<tr>
<td>low CD44 expression</td>
<td>Kergi HA et al.</td>
<td></td>
</tr>
<tr>
<td>high EGF expression</td>
<td>Sun M et al.</td>
<td></td>
</tr>
<tr>
<td>high ERCC1 expression</td>
<td>Gomez-Roca C et al.</td>
<td></td>
</tr>
<tr>
<td>high IGF-1 expression</td>
<td>Hwang CC et al.</td>
<td></td>
</tr>
<tr>
<td>high Ki-67 levels</td>
<td>Sun M et al.</td>
<td></td>
</tr>
<tr>
<td>low Neuregulin1 expression</td>
<td>Sun M et al.</td>
<td></td>
</tr>
<tr>
<td>inactivating mutation of PTEN</td>
<td>Hahn M et al.</td>
<td></td>
</tr>
<tr>
<td>high S100A7 expression</td>
<td>Zhang H et al.</td>
<td></td>
</tr>
<tr>
<td>high phosphorylated Her3 expression</td>
<td>Sun M et al.</td>
<td></td>
</tr>
<tr>
<td>high phospho-S6 expression</td>
<td>McDonald JM et al.</td>
<td></td>
</tr>
<tr>
<td>low TGF-α expression</td>
<td>Sun M et al.</td>
<td></td>
</tr>
</tbody>
</table>
in the tumor stroma contribute significantly to the outgrowth of cancer cells both at the primary site and in distant metastatic organs. The occurrence of brain metastasis reflects the culmination of such tumor-microenvironment interactions. Particularly, the specialized physiology of the brain not only contributes to the colonization of metastatic tumor lesions but also significantly affects the efficacy and outcome of therapeutic interventions. Future clinical interventions to treat patients with brain metastasis must take into consideration the impact of these important microenvironmental determinants.

DISCLOSURE OF CONFLICT OF INTERESTS

All authors have no conflict of interests.

REFERENCES


carcinoma with limited disease receiving prophylactic cranial irradiation. Cancer 104 : 811-816, 2005


